CORAL SPRINGS, Florida, February 25, 2014 /PRNewswire/ --
Consumer goods & bio/pharma companies draw attention from investors with increased production and news developments: RiceBran Technologies (NASDAQ: RIBT), Mondelez International, Inc. (NASDAQ: MDLZ), Whole Foods Market, Inc. (NASDAQ: WFM), Inovio Pharmaceuticals, Inc. (NYSE: INO) and VIVUS Inc. (NASDAQ: VVUS)
RiceBran Technologies (NASDAQ: RIBT) ("RBT"), a global leader in the production and marketing of value added products derived from rice bran, today announced that RBT is exhibiting at Booth #8623 at the upcoming Natural Products Expo West trade show from March 7 to March 9, 2014 at the Anaheim Convention Center in Anaheim, California. RBT will exhibit its range of minimally processed, hypo-allergenic, gluten free, non-GMO stabilized rice bran ingredients and patented rice bran derivatives at Natural Products Expo West, the leading trade show in the natural, organic and healthy products industry. Natural Products Expo West is expected to attract over 60,000 industry professionals and 3,000 exhibitors to the Anaheim Convention Center.
Dr. Robert Smith, SVP of Sales and Business Development for RBT commented, "Based on growing consumer demand for highly nutritious, gluten-free, vegan and minimally processed products, Natural Products Expo West is the ideal venue for exhibiting our proprietary and patented rice bran and derivative products. We will be highlighting the health and nutritional benefits that can be achieved by incorporating our ingredients into a diverse range of healthy foods from beverages, nutrition bars, cereals, and pastas to high-end companion pet nutrition products."
To read the full press release, please click here: http://www.fnmprofiles.com/profiles-ribt.html
W. John Short, CEO & President of RBT commented "Natural Products Expo West provides an excellent opportunity to highlight the enhanced capabilities resulting from our recent acquisition of H&N Distribution. In addition to delivering our individual functional ingredients, we are now in a position to provide turnkey, packaged finished product offerings to a variety of retail, direct-to-consumer and direct marketing customers based on our proprietary and patented ingredients blended with other sources of proteins and phytonutrients to produce healthy and natural products that compete effectively in the health and wellness markets."
Mondelez International, Inc. (NASDAQ: MDLZ) recently highlighted the company's competitive advantages, long-term growth targets and margin-improvement initiatives at the Consumer Analyst Group of New York (CAGNY) conference. The company also provided detailed insights into the performance and outlook of its North American business. "With an unrivaled portfolio of iconic brands, leading share positions in all of our key categories and an advantaged geographic footprint, we have the best set of assets in our industry," said Irene Rosenfeld, Chairman and CEO. "The plans we're executing now will enable us over the long term to deliver strong top-line growth, significantly expand margins, grow Adjusted EPS double digits and continue to generate solid cash flow. We believe these efforts will drive top-tier shareholder returns."
Whole Foods Market, Inc. (NASDAQ: WFM) has committed more than $5 million to fight poverty in the U.S. through its partner, Grameen America, a nonprofit microfinance organization that offers microloans, training and support to help women who live in poverty build small businesses to create better lives for their families. The money will help Grameen America launch a new microlending branch in Austin, and will support existing programs in six metro areas: New York; the Bay Area; Los Angeles; Charlotte, N.C.; Omaha, Neb.; and Indianapolis. To date, Whole Planet Foundation has committed more than $48 million for microcredit projects throughout 59 countries across Asia, Africa and the Americas.
Inovio Pharmaceuticals, Inc. (NYSE: INO) recently announced it has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. Inovio has appointed Dr. Laurent Humeau as Vice President of R&D and Dr. Jan Marie-Albert Van Tornout as Vice President of Clinical Development. Prior to Inovio, Dr. Humeau was Senior Director of Translational Research, Human Therapeutics Division for Intrexon and previously Chief Scientific Officer at VIRxSYS Corporation. At Inovio, Dr. Humeau will provide the technical and strategic leadership for its R&D group including: preclinical development of immunotherapy and vaccine candidates, immunology and immune monitoring approaches, method development, product characterization, and analytical development.
VIVUS Inc. (NASDAQ: VVUS) a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, recently provided a business update and reported its financial results for the fourth quarter and year ended December 31, 2013. On November 13, 2013, we announced that the United States Patent and Trademark Office had issued U.S. Patent Nos. 8,580,298, covering compositions of Qsymia, and 8,580,299, covering methods for effecting weight loss using Qsymia. The newly issued patents are assigned to VIVUS and are expected to extend patent exclusivity for Qsymia in the U.S. to 2029.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand five hundred dollars for news coverage of the current press release issued by RiceBran Technology by the company.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group, LLC